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Abstract
Epidemiological studies have shown obesity to be linked with poorer outcomes in breast
cancer patients. The molecular mechanisms responsible for the increased risk of invasive/
metastatic disease with obesity are complex, but may include elevated levels of adipokines
such as leptin. Using physiological levels of leptin found in obesity in a novel chronic in vitro
treatment model (200 ng/ml for 14 days), we confirmed the occurrence of leptin-mediated
changes in growth, apoptosis and metastatic behavior, and gene expression changes repre-
senting epithelial-to-mesenchymal transition (EMT) and a cancer stem cell (CSC) like phe-
notype in breast epithelial and cancer cell lines (MCF10A, MCF10AT1, MCF7 and MDA-
MB-231). Further, we have discovered that these effects were accompanied by increased
expression of TGFB1, and could be significantly reduced by co-treatment with neutralizing
antibody against TGFB1, indicating that the induction of these characteristics was mediated
via TGFB1. Occurring in both MCF7 and MCF10AT1 cells, it suggests these actions of leptin
to be independent of estrogen receptor status. By linking leptin signalling to the established
TGFB1 pathway of metastasis / EMT, this study gives a direct mechanism by which leptin
can contribute to the poorer outcomes of obese cancer patients. Inhibitors of TGFB1 are in
currently in phase III clinical trials in other malignancies, thus identifying the connection
between leptin and TGFB1 will open new therapeutic opportunities for improving outcomes
for obese breast cancer patients.
Introduction
Breast cancer is the second-leading cause of cancer-related deaths among women worldwide
[1]. Epidemiological studies have shown that obese and overweight women have poorer out-
comes in breast cancer [2, 3]. In fact, obesity is linked with many aspects of breast cancer
including higher prevalence, higher grade tumors, higher rates of metastatic, recurrent, or
drug resistant disease, and higher relative risk of death [4–7]. Both breast cancer and obesity
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are multi-factorial diseases and no single factor is responsible for the promotion of tumor pro-
gression in obese patients [8].
At the cellular level, tumor cells exist in a complex environment composed of many diverse
cells, and tumor invasion results in immediate proximity of breast cancer cells to adipocytes
in the mammary gland [9–11]. Cancer associated adipocytes are the source of a number of
secreted factors including leptin, IL6, IL1β and estrogen, and these factors have been indepen-
dently linked with breast cancer progression [12]. Leptin is a pleiotropic hormone primarily
synthesized by adipose tissues and circulating levels are higher in obese people (>100 ng/ml)
than non-obese people (5–50 ng/ml) [13, 14]. Some population studies have linked high levels
of leptin to increased risk of breast cancer, independent of obesity indices [15, 16], and a
meta-analysis of 23 studies of leptin levels and breast cancer concluded there is an association
between higher circulating levels of leptin with breast cancer occurrence and progression [17].
The contribution of leptin to breast cancer development is evident from pre-clinical studies
where mice deficient in leptin or with dysfunctional leptin receptors did not develop trans-
gene-induced mammary tumors [18, 19] and had reduced growth of transplanted tumors[20].
Numerous studies have previously shown that leptin can directly act on breast cancer cells and
modulate their behavior, including promoting proliferation, transformation and reducing
apoptosis (reviewed in [21]), however the effect of leptin on the metastatic process is relatively
poorly understood.
The epithelial-to-mesenchymal transition (EMT) is often activated during metastasis and is
directly linked to the acquisition of cancer stem cell (CSC) properties [22]. CSCs can mediate
metastasis and are associated with drug resistance and poorer clinical outcomes [23, 24].
There are numerous signalling pathways involved in EMT including MAPK/PI3K, TGFB1/
SMAD and Wnt/β-catenin [25]. Leptin activates a number of signalling pathways that have
been previously described as important in cancer promoting events and that overlap with the
induction of EMT, including MAPK and Wnt/β-catenin [26–28], however leptin signalling
through the TGFB1 pathway, a major player in EMT, has not been demonstrated in breast
cancer.
We have examined the effect of chronic, physiological leptin treatment on the metastatic
and CSC-like characteristics of breast epithelial and cancer cells, and have discovered that pro-
motion of invasiveness and CSC behavior by leptin is mediated through binding of TGFB1 to
its receptor, increasing the likely contribution of leptin signalling to poorer outcomes in obe-
sity, and adding to the list of pathways that may be readily targeted in obese cancer patients.
Materials and methods
Cell culture
Breast epithelial and cancer cells were obtained from American Type Culture Collection
(ATCC, Manassas, USA) at the start of this project, and experiments were completed within
35 passages of the cell growth. MCF7 and MDA-MB-231 cells were maintained in DMEM
containing phenol red, 10% fetal bovine serum (FBS), 1% combination of penicillin, strepto-
mycin and neomycin (PSN). MCF10A and MCF10AT1 cells were cultured in DMEM/F12
containing phenol red, 5% (MCF10A) or 2.5% (MCF10AT1) horse serum, 0.01mg/ml insulin,
500ng/ml hydrocortisone, 20ng/ml epidermal growth factor and 1% PSN. During treatments,
serum content of the media was decreased to 2% (low serum media).
Cell proliferation and apoptosis
For proliferation assays, cells were treated for 72hr (acute treatment) with leptin or vehicle in
low serum media and the rate of cell proliferation was estimated with Vybrant MTT cell
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proliferation assay kit (Invitrogen). Cell numbers were estimated from a standard curve. For
apoptosis, cells were treated for 24hr with leptin or vehicle in low serum media, trypsinized
and collected with media to avoid loss of apoptotic/dead floating cells. Apoptotic cells were
measured with Annexin V-FITC/PI kit (Invitrogen). Data was acquired on LSR Fortessa Cell
Analyzer (BD Biosciences) and analyzed with Flowjo software (Treestar Flowjo, Version
10.0.6) and presented as % apoptotic cells. Experiments were performed in triplicate, and at
least 3 independent experiments conducted.
Chronic leptin treatment conditions
Obesity is a chronic disorder, thus to mimic this, long term treatment of cells was used in these
studies, unless otherwise stated. Conditions were based on two publications, Mani et al. and
Morel et al., which studied the induction of EMT in mammary epithelial cells [22, 29]. Low
serum media was used during chronic treatment to decrease the factors present in serum
which may have a background effect or that can form complexes with recombinant proteins
used in this study. Breast cancer cells were seeded in normal culture media and cultured over-
night. Medium was then replaced with low (2%) serum media. Cells were again cultured over-
night before addition of treatments (vehicle, leptin (200 ng/ml), TGFB1 (2.5 ng/ml) and
neutralizing antibody against TGFB1 (5 ng/ml): Ab-TGFB1 (Sigma-Aldrich)). Low serum
media with treatment was changed every third day and cells were sub-cultured once they
reached 70–80% confluence. Treatment was continued for 14 days, and cells were harvested
and replated as appropriate for each assay.
Hanging drop assay
The hanging drop assay measures the ability of cells to aggregate, an important property of
non-invasive epithelial cells [30]. Cells were trypsinized and resuspended in DMEM containing
10% FBS at 1x106 cells/ml. Cells (20μl) were placed on the lid of a 6-well plate. The lid was
inverted and placed on the plate that contained media to maintain humidity and prevent evapo-
ration. Cells were cultured overnight and then photographed using Olympus 1X71 at 40x objec-
tive (three different fields of view per drop). At least three drops per treatment were performed,
and experiments repeated at least 3 times. The area of individual aggregates formed (size range
approximately 50–200μm) was measured using NIH ImageJ software and expressed as pixels2.
Matrigel invasion assay
Cells were trypsinized and resuspended in DMEM containing 1% FBS at 1x105 cells/ml. Cells
(5,000) were seeded into cell inserts (Sigma-Aldrich) pre-coated with matrigel (BD Biosci-
ences). The lower chamber was filled with DMEM containing 10% FBS. After 24hr, cells were
fixed, stained with Giemsa stain and cells that had invaded the matrigel were counted. Treat-
ments were performed in triplicate, and experiments repeated at least 3 times. Data is
expressed as a number of invaded cells/5,000 cells.
Cell migration
After 14 days of treatment, cells were trypsinized, resuspended and seeded at equal densities in
96-well plates in standard medium and allowed to adhere overnight. Treatments (eg. leptin,
200 ng/ml in low serum) were then continued until cells reached 100% confluence (usually
overnight). Confluent cells were scratched with a 96-pin wound maker (Essen Biosciences,
Michigan, USA), plates were washed twice with media to remove any cell debris, and wells
replenished with low serum media containing treatments. Cells were scanned inside an
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incubator every 2 hr for 24 hr with Incucyte Kinetic Imaging System (IncuCyte 2011A, Essen
Biosciences). The rate of cell migration (μm/hr) was calculated over the first 12 hr, well within
the population doubling time for these cells to minimize the impact of any proliferative effects
of treatments on the assay.
Mammosphere formation assay
After 14 days of leptin treatment (200 ng/ml), cells were trypsinized, resuspended and seeded
at 50,000 cells per well in 6-well ultra-low attachment plates (Costar). Cells were grown in spe-
cialized medium containing mammocult proliferation supplement (StemCell Technologies,
British Columbia, Canada), heparin (StemCell Technologies, British Columbia, Canada) and
1% methylcellulose (Sigma-Aldrich, MO, USA). Leptin treatment was continued during mam-
mosphere formation. Mammospheres were counted after 7 days and data was expressed as
number of colonies per 5,000 cells seeded. Experiments were performed in triplicate and
repeated independently at least 3 times.
Quantitative polymerase chain reaction
Total RNA was extracted with Qiazol and RNeasy Mini kit (Qiagen, Maryland, USA). DNA was
removed using DNase (Qiagen). RNA was converted to cDNA using Omniscript Reverse Tran-
scriptase kit and Oligo(dT)12-16 kit (Qiagen). Predesigned primers sequences were obtained
from PrimerBank (Table 1). qPCR was performed with SYBR green Mastermix (Applied Biosys-
tems) on 7900HT Fast Real-Time PCR system (Applied Biosystems) using the amplification pro-
tocol: 50˚C for 2 minutes, 95˚C for 10 minutes, followed by 40 cycles at 95˚C for 15 seconds and
60˚C for 1 minute. Dissociation curve analysis was also applied to confirm specific amplification.
Expression levels were normalized to the house-keeping gene hypoxanthine-guanine phosphori-
bosyltransferase (HPRT1) and results were analyzed as relative expression to HPRT1. Where
results involve leptin treatment, they are presented as fold-change compared to untreated cells.
Each experiment included at least 3 biological replicates, and results shown are representative of
at least 3 independent experiments with consistent outcomes. In some cases, biological replicates
from independent experiments were combined for statistical analysis.
Western blotting
Western blotting was performed by standard protocols with enhanced chemiluminescence
(ECL) detection. Protein was extracted from cells using MPER extraction buffer (Thermo Sci-
entific, #78503). Protease inhibitors (Roche, #04 693 159 001) were used in all samples while
phosphatase inhibitor (Calbiochem, #524629) was used when checking phosphorylated pro-
teins (P-STAT3). Total protein was estimated using BCA protein assay kit (Thermoscientific,
#23225). Equal amounts of protein (50μg) were separated by SDS-PAGE and transferred to
PVDF membrane. The membrane was blocked with 5% BSA and specific proteins detected
with the following primary antibodies: anti-leptin receptor (Abcam, #104403), anti-STAT3
(Cell Signalling, #9132), anti-phospho-STAT3 (Tyr705) (Cell Signalling, #9131) and anti-β-
actin (loading control, Abcam, #Ab8227). Anti-rabbit IgG, HRP-linked secondary antibody
(Cell Signalling, #7074) was used for ECL detection.
FACS analyses
Fluorescence activated cell sorting (FACS) readings were acquired on LSR Fortessa cell analy-
ser (BD Biosciences) and analysed with Flowjo software (Treestar Flowjo, Version 10.0.6).
Experiments were performed in triplicate and repeated independently at least 3 times.
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Aldefluor assay. Aldehyde dehydrogenase (ALDH) is the enzyme required for conversion
of retinol to retinoic acid and is highly expressed in cells with stem like properties[23]. ALDH
activity was assessed using the Aldefluor assay kit (StemCell Technologies, British Columbia,
Canada). After 14 days of treatment, cells were resuspended at 106 cells/ml in aldefluor buffer.
Aldefluor reagent (5ul) was added and cells were incubated in the dark at 37˚C for 45min.
Cells were washed, resuspended in 500ul of aldefluor buffer, and intracellular fluorescence
measured by FACS and presented as % aldefluor positive cells. A negative control of diethyla-
minobenzaldehyde (DEAB) was set in parallel to control for background fluorescence.
CD44/CD24 CSC markers. The CD44+/CD24- subset of human breast cancer cells are
considered a CSC population of cells [31]. Anti-CD44-APC (BD Biosciences, #559942, 20μl/
106 cells) and anti-CD24-PE (BD Biosciences, #555428, 10–20μl/106 cells) were used to esti-
mate the percentage of CD44+/CD24- cells in cultured populations. After 14 days of treatment,
cells were resuspended in FACS buffer (PBS, 1% FBS) with antibodies for 40 min on ice on
shaker in the dark. After washing, fluorescence readings were acquired and data was expressed
as % CD44+/CD24- cells.
TGFB1 expression. TGFB1 expression was measured with FACS. After 14 days of treat-
ment, cells were fixed with neutral buffered formalin and permeabilized with 1% SDS. PE-Mouse
anti-human TGFB1 (BD Biosciences, #562339, 5μl/106 cells) was added and incubated in the dark
Table 1. Sequences of primers used for quantitative RT-PCR.
Name NCBI gene symbol Primer sequence
Hypoxanthine phosphoribosyltransferase 1 HPRT1 F. 5’-CCTGGCGTCGTGATTAGTGAT-3’
R. 5’-AGACGTTCAGTCCTGTCCATAA-3’
Glyceraldhyde-3-phosphate dehydrogenase GAPDH F. 5’-CATGAGAAGTATGACAACAGCCT-3’
R. 5’-AGTCCTTCCACGATACCAAAGT-3’
Leptin receptor (functional, long form) LEPR F. 5’-TGCCACCAAATTCAACCTATGAC-3’
R. 5’-TGCTCACTCCGAAAGCAACAG-3’
Adiponectin receptor 1 ADIPOR1 F. 5’-TCCTGCCAGTAACAGGGAAG-3’
R. 5’-AGGGGAAGTGTCAGTACCCG-3’
Adiponectin receptor 2 ADIPOR2 F. 5’-CCCTCTCTTACAAGCCCATCA-3’
R. 5’-CCGACCTTCCCATACCTTACAAA-3’
Cadherin 1, type 1, epithelial cadherin CDH1 F. 5’-CGAGAGCTACACGTTCACGG-3’
R. 5’-GGGTGTCGAGGGAAAAATAGG-3’
Snail homolog 2 (SLUG) SNAI2 F. 5’-ATACCACAACCAGAGATCCTCA-3’
R. 5’-GACTCACTCGCCCCAAAGATG-3’
Signal transducer and activator of transcription 3 STAT3 F.5’-CAGCAGCTTGACACACGGTA-3’
R.5’-AAACACCAAAGTGGCATGTGA-3’
Jun proto-oncogene C-JUN F.5’-GTCCTTCTTCTCTTGCGTGG-3’
R.5’-GGAGACAAGTGGCAGAGTCC-3’
FBJ murine osteosarcoma viral oncogene homolog C-FOS F.5’-GTGGGAATGAAGTTGGCACT-3’
R.5’-CTACCACTCACCCGCAGACT-3’
Transcription growth factor, β receptor 1 TGFBRI F. 5’-GCTGTATTGCAGACTTAGGACTG-3’
R. 5’-TTTTTGTTCCCACTCTGTGGTT-3’
Transcription growth factor, β receptor 2 TGFBRII F. 5’-GACATCAATCTGAAGCATGAGAACA-3’
R. 5’-GGCGGTGATCAGCCAGTATT-3’
SMAD family member 2 SMAD2 F. 5’-GCTGTTTTCCTAGCGTGGCTT-3’
R. 5’-TCCAGACCCACCAGCTGACT-3’
SMAD family member 3 SMAD3 F. 5’-CGGCAGTAGATGACATGAGG-3’
R. 5’-TCAACACCAAGTGCATCACC-3’
https://doi.org/10.1371/journal.pone.0178454.t001
Leptin signals through TGFB1 in breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0178454 May 25, 2017 5 / 21
at room temperature for 40min. After washing and resuspending in FACS buffer, fluorescence
readings were acquired and data was expressed as % high TGFB1 expressing cells.
Statistical analysis
GraphPad software (GraphPad Prism, version 6) was used to perform statistical analysis. Data
are presented as mean ± SEM with the sample size, type of statistical analysis and P values pre-
sented in the figure legends.
Results
Breast cancer cells express LEPR and increase proliferation in response
to leptin
We first examined expression of the adipokine receptors, LEPR (functional leptin receptor),
ADIPOR1 and ADIPOR2 (adiponectin receptors) in four cell lines chosen to represent different
states of progression or subtypes of breast cancer: MCF10A (immortal, non-cancerous),
MCF10AT1 (isogenic cancerous pair to MCF10A, transformed in vitro), MCF7 (luminal, hor-
mone receptor positive, non-metastatic) and MDA-MB-231 (basal, hormone receptor negative,
metastatic). LEPR mRNA was expressed in all cell lines (Fig 1A). MCF10A and MCF10AT1
cells did not differ in LEPR mRNA expression, whereas higher expression of LEPR mRNA (Fig
1A) was found in MDA-MB-231 compared to MCF7 cells. To determine if mRNA differences
were reflected in protein levels, LEPR protein was investigated by western blotting in the two
patient-derived breast cancer cell lines where mRNA levels differed the most. The mRNA differ-
ence was reflected in protein expression, although to a much lesser extent, and while MCF7
cells showed the lowest mRNA levels, LEPR protein was readily detected by western blotting
(Fig 1B). ADIPOR1 and ADIPOR2mRNA were detectable in all cell lines, but there were no
remarkable differences in expression (data not shown).
As our hypothesis was that leptin would increase metastatic cell behaviour, we focused on
the less invasive MCF7 and MCF10AT1 cells. To confirm that the breast cancer cells were
responsive to leptin in our culture conditions, we measured cell proliferation as leptin has been
shown to induce proliferation in a variety of cells [32–34]. A dose-dependent increase in cell
proliferation after 3 days of acute leptin treatment was observed in both MCF7 and MCF10AT1
cells, with 200 ng/ml leptin resulting in 2.12-fold (MCF7) and 1.5-fold (MCF10AT1) more cells
than controls (Fig 1C and 1D). Leptin treatment made a small but not significant decrease in
the background percentage of apoptotic cells in both MCF7 and MCF10AT1 cells, such that the
increase in cell number could not be accounted for by decreased background apoptosis in this
time frame (data not shown).
Chronic leptin decreased cell aggregation, and increased cell migration
and invasion
Obesity is a chronic disorder, thus we examined the morphology of breast cancer cells after 14
days of 200 ng/ml leptin treatment in low serum conditions for changes consistent with
increased invasiveness and EMT. After leptin treatment, MCF7 cells were more dispersed and
more spindle-like in structure, with less cell-to-cell attachment than control cells (Fig 2A and
2B). Similar changes were also observed in MCF10AT1 cells (images not shown). The acquisi-
tion of a mesenchymal phenotype was assessed with functional assays. Leptin significantly
decreased the size of MCF7 cell aggregates (Fig 2C), almost doubled the number of MCF7 cells
invaded into matrigel (Fig 2D) and significantly increased the migration speed of MCF7 and
MCF10AT1 cells (Fig 2E and 2F).
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Leptin decreased epithelial and increased mesenchymal and CSC
characteristics
To examine the loss of epithelial characteristics at the molecular level, changes in the mRNA
expression of CDH1 (E-cadherin) and SNAI2 (snail family zinc finger 2) in MCF7 and
MCF10AT1 cells after chronic leptin treatment were measured by qPCR. Loss of epithelial
characteristics were indicated by significantly decreased CDH1mRNA expression (Fig 3A and
3B) while gain of mesenchymal characteristics were indicated by an increase in SNAI2 (Fig 3C
and 3D). These changes were dose-dependent in MCF7 cells.
An EMT can be considered intermediate in the process of stem cell development [22]. We
examined whether leptin-induced changes included changes to breast CSC markers. Leptin
treatment significantly increased the percentage of aldefluor positive cells in both MCF7 and
MCF10AT1 cells in a dose dependent manner (Fig 4A and 4B). Similarly, the CSC population
as defined by the cell surface markers CD44+/CD24- was significantly increased in both breast
cancer cell lines by leptin (Fig 4C and 4D). As the expression of these CSC markers is highly
Fig 1. Breast cancer cells express LEPR and increase proliferation in response to leptin. (a) LEPR mRNA (qPCR, relative to HPRT1) and (b)
LEPR protein expression (western blot) in breast epithelial cell lines. (Student’s t-test was used to compare differences in mRNA levels between pairs
of cell lines—MCF10A vs MCF10AT1 and MCF7 vs MDA-MB-231. n = 9–11 wells combined from several experiments.) ***P<0.001. (c) MCF7 and
(d) MCF10AT1 cells increased proliferation in response to 72 hr of acute leptin treatment, as measured by MTT assay. (n = 6–8 wells. ANOVA was
used to compare among groups with Tukey’s multiple comparison test. **P<0.01, ***P<0.001 compared to control (CTRL)).
https://doi.org/10.1371/journal.pone.0178454.g001
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Fig 2. Leptin decreased cell aggregation, and increased cell migration and invasion. MCF7 or
MCF10AT1 cells in low serum media were treated for 14 days with 200 ng/ml leptin (LEPT) and compared to
Leptin signals through TGFB1 in breast cancer
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variable across cells lines, we functionally tested the stemness of the breast cancer cells using
the mammosphere formation assay. Leptin treated MCF7 and MCF10AT1 breast cancer cells
formed significantly more mammospheres than control cells (Fig 4E and 4F). These results
indicate that chronic leptin treatment of breast cancer cells can directly alter their characteris-
tics in a manner consistent with the more aggressive phenotype and poorer outcomes that are
observed in obese patients.
untreated controls (CTRL). (a) CTRL and (b) LEPT-treated MCF7 cells are morphologically different. (c) Effect
on MCF7 cells by hanging drop cell aggregation assay. ***P<0.001 (n = 5 drops, Student’s t-test. Data shown
is from one representative experiment of 3 independent experiments.) (d) Effect on invasion of MCF7 cells into
matrigel. ***P<0.001 (n = 18–20 wells, Student’s t-test, data combined from 3 independent experiments). (e)
and (f) Effect on migration rate of (e) MCF7 and (f) MCF10AT1 cells measured by wound healing scratch
assay. ***P<0.001 (n = 17–24 wells, Student’s t-test, data combined from several independent experiments).
https://doi.org/10.1371/journal.pone.0178454.g002
Fig 3. Leptin induced epithelial to mesenchymal transition indicated by mRNA markers. Effect of leptin treatment on mRNA expression of
CDH1 (a and b, n = 8 and 3) and SNAI2 (c and d, n = 5 and 9) in MCF7 (a and c) or MCF10AT1 (b and d) cells. qPCR was normalised to HPRT1
expression and is presented as fold-change compared to untreated control (CTRL). ANOVA was used to compare among groups with Tukey’s multiple
comparison test. *P<0.05, **P<0.01, ***P<0.001 compared to CTRL.
https://doi.org/10.1371/journal.pone.0178454.g003
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TGFB1 expression was induced by leptin and mediated leptin-induced
changes
TGFB1 is a central player in EMT and cross-talks with other EMT signalling pathways. Thus,
we examined the role of TGFB1 in leptin-induced EMT and CSC changes. In Fig 1A and 1B,
we demonstrated the presence of LEPR on breast cancer cells. To investigate the presence of
functional LEPR and TGFB1 signalling, the downstream components of these signalling path-
ways were measured at the mRNA level by qPCR. LEPR, STAT3, JUN (c-Jun), FOS (c-Fos)
were expressed in both MCF7 and MCF10AT1 breast cancer cell lines (Fig 5A) indicating the
presence of LEPR signalling components in these cells, while western blotting after chronic
leptin treatment indicated increased STAT-3 phosphorylation, demonstrating active leptin sig-
nalling (Fig 5B), consistent with the observed proliferation effect (Fig 1). Similarly, compo-
nents of TGFB1 signalling, TGFBR1,TGFBR2, SMAD2, SMAD3were expressed in both MCF7
and MCF10AT1 cells indicating the possible presence of intact TGFB1 signalling (Fig 5C). The
effect of leptin treatment on intracellular TGFB1 protein levels was estimated by FACS. Leptin
treatment resulted in an overall increase in TGFB1 protein levels (Fig 6A and 6B) and the per-
centage of cells with high anti-TGFB1 fluorescence was significantly increased in a dose-
dependent manner, with 5.4-fold and 7.1-fold increases observed in MCF7 and MCF10AT1
cells respectively after 200 ng/ml leptin treatment (Fig 6C and 6D).
We next confirmed the involvement of TGFB1 in leptin-induced EMT and CSC changes by
co-treating cells with neutralizing antibody against TGFB1 (Ab-TGFB1). The induction of
EMT by leptin as indicated by decreased CDH1mRNA expression could be mimicked by
TGFB1 treatment, and was almost completely blocked by co-treatment of the cells with Ab-
TGFB1 in both MCF7 and MCF10AT1 cells (Fig 7A and 7B). At the functional level, a similar
effect of Ab-TGFB1 was also observed for the increased rate of cell migration after leptin treat-
ment (Fig 7C and 7D) and for aldefluor activity in both cell lines (Fig 7E and 7F). These results
clearly indicate a role for the TGFB1 receptor in the leptin-mediated changes in breast cancer
cell characteristics. Fig 8 shows a schematic representing the proposed autocrine/paracrine
TGFB1 signalling in breast cancer cells resulting from leptin exposure.
Discussion
The association between obesity and poorer outcomes from breast cancer is clear, however the
mechanisms underlying this are complex. In this study, four steps in the cancer progression
process were found to be significantly altered by leptin, namely cell proliferation, EMT, inva-
siveness and cell migration. Leptin treatment in both MCF7 and MCF10AT1 cells increased
proliferation (Fig 1), and altered CDH1 and SNAI2 expression indicating EMT (Fig 3). An
increase in metastatic potential was confirmed by measuring decreased cell aggregation,
increased cell migration, and increased invasiveness through matrigel (Fig 2). We also found
leptin to increase the stemness of both cancer cell lines, as indicated by aldefluor activity,
CD44/CD24 expression, and mammosphere formation (Fig 4). This suggests that higher circu-
lating levels of leptin present in obese breast cancer patients might be contributing to the
development of higher grade and more metastatic tumors by these direct actions of leptin on
Fig 4. Leptin increased stem cell characteristics of breast cancer cells. Effect of leptin treatment (14 d in
low serum conditions) on: aldefluor activity in (a) MCF7 (n = 7) and (b) MCF10AT1 (n = 6) breast cancer cells;
CD44+/CD24- cell population in (c) MCF7 (n = 6) and (d) MCF10AT1 (n = 6) cultures; mammosphere
formation by (e) MCF7 (n = 6) and (f) MCF10AT1 (n = 8) cells. (c-f) Leptin treatment was 200 ng/ml. (ANOVA
was used to compare among groups with Tukey’s multiple comparison test (a and b). Student’s t-test was
used to compare two groups (c-f).) *P<0.05, **P<0.01, ***P<0.001 compared to CTRL.
https://doi.org/10.1371/journal.pone.0178454.g004
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Fig 5. Leptin and TGFB signalling components are present. (a) mRNA expression of components of
LEPR signalling: LEPR, STAT3, C-JUN, and C-FOS; (b) Effect of leptin treatment (200 ng/ml, 14d, low
Leptin signals through TGFB1 in breast cancer
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breast cancer epithelial cells. Interestingly, one study has reported higher leptin levels in breast
cancer tissue compared to normal breast tissue from the same patient [35], suggesting elevated
local production of leptin in the tumor microenvironment. This may arise from cancer associ-
ated fibroblasts (CAFs) which have been recently shown to secrete leptin, mediating cross-talk
serum) on phosphorylated STAT3 (STAT3-P) levels (with total STAT3 and β-actin loading controls) in MCF7
cells by western blotting. (c) mRNA expression of components of TGFB1 signalling: TGFBR1, TGFBRII,
SMAD2, SMAD3; in MCF7 and MCF10AT1 cells (n = 6 per group) (qPCR, relative to HPRT1).
https://doi.org/10.1371/journal.pone.0178454.g005
Fig 6. Increased TGFB1 protein expression in response to leptin. (a and b) FACS histograms showing increased intracellular TGFB1 levels in (a)
MCF7 and (b) MCF10AT1 cells after chronic 200 ng/ml leptin treatment. (Red line–untreated control, Blue line–Leptin treated 200 ng/ml for 14 days.)
(c and d) Dose responses for TGFB1 protein levels after leptin treatment in (c) MCF7 (n = 6) and (d) MCF10AT1 (n = 6) cells. (ANOVA was used to
compare among groups with Tukey’s multiple comparison test.) *P<0.05, **P<0.01, ***P<0.001 compared to CTRL.
https://doi.org/10.1371/journal.pone.0178454.g006
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Fig 7. Neutralizing antibody against TGFB1 blocks leptin mediated actions. Effect of leptin (200 ng/ml), TGFB1 (2.5 ng/ml), Ab-
TGFB1 (5 ng/ml), Ab-TGFB1+Leptin or Ab-TGFB1+TGFB1 treatment (all treatments for 14 days) compared with untreated controls
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between CAFs and breast cancer cells to drive growth and invasion [36], mammosphere for-
mation and stemness [37]. This extends the relevance of the adverse actions of leptin to non-
obese women with normal circulating leptin levels.
Our findings are consistent with those of Yan et al. who reported that leptin induces EMT
in several breast cancer cell lines treated in serum-starved conditions for only 4 days [28]. Con-
ditions of leptin treatment in published studies varies considerably, from acute (1–4 days)
physiological levels (50–200 ng/ml), to supraphysiological concentrations (up to 1600 ng/ml)
for 2 days [38], often in serum starvation conditions. Our conditions are low serum for 14
days, a chronic treatment protocol that is perhaps more representative of the actual clinical
condition of obesity, and may explain why the magnitude of many of the changes we observed
are less than those reported by Yan et al. Some epidemiological studies have suggested that
there are substantial differences between the association of obesity and breast cancer based on
premenopausal and postmenopausal status [39–41] and have linked obesity as a risk factor in
postmenopausal women via the production of estrogens by adipose tissue. Further, there is
cross-talk between estrogen and leptin signalling [21], such that leptin may increase estrogen
levels by increasing aromatase expression [42], and estrogen may enhance the actions of leptin
on: (a and b) CDH1 mRNA expression in (a) MCF7 & (b) MCF10AT1 cells (qPCR was normalised to HPRT1 expression and is
presented as fold-change compared to untreated control (CTRL)); (c and d) cell migration rate of (c) MCF7 and (d) MCF10AT1 cells;
and (e and f) aldefluor activity of (e) MCF7 and (f) MCF10AT1 cells. (ANOVA was used to compare among groups with Tukey’s
multiple comparison test. Data was combined from 2–3 experiments representative of at least 3 independent experiments.) *P<0.05,
**P<0.01, ***P<0.001 compared to CTRL.
https://doi.org/10.1371/journal.pone.0178454.g007
Fig 8. Schematic summary of the proposed autocrine / paracrine TGFB1 signalling in breast cancer.
Leptin synthesized and secreted by adipose tissues (or cancer associated fibroblasts) will bind to the leptin
receptor (LEPR) on cancer cells, activating JAK/STAT3 signalling. c-Jun, c-fos and AP-1 complex are
recruited to the promoter of the TGFB1 gene, increasing synthesis of TGFB. TGFB1 is secreted and binds to
its receptors (TGFBRI and TGFBRII) expressed on cancer cells and activates SMAD2/3, recruiting SMAD2/3/
4 to the nucleus with Transcription Factors (TFs) and co-factors (CFs), hence repressing CDH1 expression.
https://doi.org/10.1371/journal.pone.0178454.g008
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via increasing leptin-induced STAT3 activity [43]. However, our study and that of Yan et al.
indicate clearly that leptin can directly induce adverse changes in breast cancer cell characteris-
tics, and these effects are not restricted to estrogen-dependent breast cancer cells, as they
occurred in both hormone receptor positive (MCF7) and negative (MCF10AT1, MDA-MB-
468 and MDA-MB-231) cell lines. This is also supported by Zheng et al. who describe a mesen-
chymal-to-epithelial transition, reduced tumor spheres and tumour outgrowths in MDA-
MB-231 cells after LEPR silencing [44]. These studies were performed in serum-free media,
further supporting the EMT actions of leptin to be independent of steroid receptor signalling,
although a contribution from phenol red in the media cannot be excluded. Further studies
using charcoal stripped serum or ER knockdown strategies are warranted to fully elucidate the
contribution of ER to the EMT actions of leptin mediated by TGFB or other signalling path-
ways, as clinical ER pathway antagonists may be useful in combination therapy strategies.
The above studies confirm that chronic leptin exposure can produce the same EMT- and
CSC-like changes reported by others who used acute leptin treatment. We have also identified
binding of TGFB1 to its receptor as a new pathway contributing to the leptin-induced EMT
and CSC effects on breast cancer cells. We demonstrated that leptin treatment of breast cancer
cells can increase TGFB1 expression (Fig 6). Further, when TGFB1 is blocked by use of a
TGFB1 neutralizing antibody, the actions of leptin promoting EMT and CSC phenotypes are
also blocked, thus strongly suggesting that TGFB1 is involved in mediating the leptin-driven
EMT/CSC phenotype (Fig 7). While our mechanistic experiments on TGFB signalling are not
extensive, the fact that we can show a significant contribution to the EMT actions of leptin
even in the context of low serum conditions and some background of estrogen receptor activ-
ity points to the likely significance of our finding in a physiological setting, and warrants fur-
ther investigation in future studies. We propose that this occurs in an autocrine manner,
where leptin induces TGFB1 expression and secretion, which then acts on TGFBRI and
TGFBRII receptors of breast cancer cells (Fig 8). While the role of TGFB1 in EMT is well estab-
lished, its placement downstream of leptin signalling is evident in only limited studies. A
diverse range of normal cells show increased secretion and/or mRNA levels of TGFB1 after
acute in vitro treatment with leptin [45–47]. In prostate cancer cell lines, leptin treatment
increased TGFB1 secretion 2-3-fold in a time and dose dependent manner [48], and in A549
lung cancer cells, leptin exposure increased TGFB1 expression, enhanced metastasis and EMT
induction that was inhibited by siRNA against TGFB1 [49]. Note our chronic leptin treatment
regime, unlike many acute treatment studies, would allow adequate time for TGFB1 to be tran-
scribed, translated, secreted and activated, allowing observation of the maximal contribution
of TGFB to EMT [29]. Thus, with both expression and intervention studies in two breast can-
cer cell lines, we extend the significance of the TGFB1 pathway to being a downstream media-
tor of leptin signalling for EMT / CSC changes in breast cancer cells.
Cross talk between TGFB1 and leptin signalling pathways may amplify the effects of either
of these ligands and call for combination therapies. In addition to TGFB1 being downstream
of leptin, interactions between TGFB1 and leptin signalling have been observed in kidney
fibroblasts where leptin treatment strongly enhanced Smad2/3 phosphorylation by TGFB1,
indicating leptin can be a co-factor for TGFB1 signalling in vitro [50]. JAK/STAT3 is a major
signalling pathway for leptin action [51] and JAK/STAT3 can be a signalling intermediate for
EMT via TGFB1 in cancer [52]. Leptin-induced EMT can occur through β-catenin activation
via Akt/GSK3 and MTA1/Wnt1 protein-dependent pathways [28]. Zhou et al. demonstrated
that TGFB1 activates β-catenin-dependent signalling and synergizes with the Wnt/β-catenin
signalling pathway to induce EMT [53]. CAFs could also respond to leptin to increase TGFB1
for paracrine signalling [21] thus targeting TGFB1 and leptin signalling could target both can-
cer cell and CAF contributions to these synergistic metastatic pathways in tumors.
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The relationship between TGFB1 and leptin signalling leads to the suggestion that treat-
ment of obese breast cancer patients with drugs that can reduce leptin levels or antagonize
TGFB1 signalling may be beneficial in prevention of metastatic disease. Several peptide antag-
onists of LEPR (allo-aca, PEG-LPrA2 and LDFI) have been shown independently to be effec-
tive against both estrogen receptor positive (MCF7) or negative (MDA-MB-231) breast cancer
xenograft models [54–56]. Clinical development of TGFB1 inhibitors is more advanced, with
several agents in phase III clinical trials (reviewed in [57]). These TGFB1 inhibitors can be
grouped in 3 mechanistic categories–anti-TGFB antibodies, anti-sense oligonucleotides
against TGFB, and TGFB receptor kinase inhibitors [57]. Our studies support consideration of
two of these categories for use to reduce the impact of leptin on cancer progression. We have
demonstrated that antagonizing the TGFB-TGFB-receptor interaction can reduce the EMT-
promoting effects of leptin (Fig 7), an effect that should be able to be mimicked with the clini-
cal anti-TGFB antibodies. Further, we have demonstrated that leptin treatment increased
intracellular TGFB protein (Fig 6), which should be able to be antagonized with TGFB anti-
sense oligonucleotides. We have not investigated (eg. via showing increased p-SMAD2/
SMAD3) the activation of the TGFB receptor kinase by leptin and so cannot comment on the
rationale for applying the kinase inhibitors against the actions of leptin. Future studies demon-
strating the reduction of the actions of leptin with these clinical TGFB-targeting agents would
be very valuable. More immediately though, the TGFB inhibitor trials do not specifically target
obese patients, but our findings suggest that stratification of patients according to body mass
index (BMI) would be of interest, as obese patients may derive more benefit. However, it must
be cautioned that TGFB has both proliferative and growth inhibitory actions, depending on
the concentration and cell context (normal vs cancerous), thus while long term use of antago-
nists may reduce metastatic disease developing from existing cancers, it may also come with
increased risk of developing new tumors [58]. The anti-diabetic drug metformin is another
therapeutic option that can decrease leptin levels in normal weight or obese non-diabetic peo-
ple [59–62], inhibit TGFB signalling [63, 64], inhibit STAT3 signalling [65] and block EMT/
CSC induction [66]. Thus, metformin may work through several pathways identified in this
report to reduce metastases and improve outcomes in obese and non-obese patients.
This study strengthens the potential significance of leptin in breast cancer progression and
identifies the TGFB1 receptor as a functionally important and novel route mediating the
actions of leptin in promoting metastasis. This opens up new therapeutic opportunities via
agents that block TGFB1 receptor and reduce TGFB1 expression that are in currently in phase
III clinical trials in other malignancies. A better understanding of the pathways involved in
poor cancer outcomes due to obesity will allow us to use rational combinations of agents such
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